Get the Daily Brief
Latest Biotech News
Blood clock: p‑tau217 predicts when Alzheimer’s symptoms will start
Researchers at Washington University School of Medicine built models using plasma p‑tau217 to estimate the likely age of symptomatic Alzheimer’s disease onset, with average uncertainty of three to...
Electronic meshes bridge tissues and electronics: organoids go 'cyborg'
Teams at the University of Pennsylvania/Harvard and Northwestern unveiled soft, ultra‑thin electronic interfaces that integrate with lab‑grown tissues to capture and modulate activity....
Element unveils Vitari: high‑throughput sequencing hits $100 genome goal
Element Biosciences introduced Vitari, its first high‑throughput sequencer that produces roughly 3 terabases per paired‑end 150 bp run in 36 hours and aims to drive the cost of a 30X human genome...
Biomanufacturing build‑out: Lonza scales ADC tooling; J&J invests $1B in cell therapy
Lonza expanded advanced synthesis capabilities for antibody‑drug conjugates (ADCs) at its Oss, Netherlands site by integrating Synaffix‑derived GlycoConnect, HydraSpace polar spacers and toxSYN...
Organoids expose indirect liver toxicity; vascularized liver 'tissueoid' models advance
A Nature Communications study using multi‑lineage hepatic organoids revealed a mechanism of drug‑induced liver injury driven by toxic exosomes released from damaged cells — an indirect hepatotoxic...
FDA reconsiders Moderna: flu mRNA shot back on review
The FDA reversed a recent refusal-to-file and agreed to review Moderna’s mRNA seasonal influenza vaccine mRNA-1010, assigning a PDUFA target date of Aug. 5, 2026. Moderna will seek full approval...
Tempus sued over genetic-data transfers: class action filed in Illinois
A class-action complaint in the Northern District of Illinois alleges Tempus AI compelled Ambry Genetics to disclose customer genetic data without consent after acquiring Ambry in a $600 million...
Korsana surfaces with $175M — Alzheimer’s antibody push begins
Boston-based Korsana Biosciences emerged from stealth with $175 million in seed and Series A backing to advance KRSA-028, a shuttle-equipped monoclonal antibody targeting amyloid beta, the company...
Compass posts second Phase III win – psychedelics stocks rally
Compass Pathways reported positive results from a second Phase III trial of its synthetic psilocybin therapy COMP360 for treatment‑resistant depression, with the high-dose arm showing...
Novartis signs big macrocycle pact: up to $1.8B with Unnatural Products
Novartis struck a research and licensing collaboration with Unnatural Products to apply UNP’s AI‑guided macrocyclic peptide platform against cardiovascular targets, a deal that could deliver up to...
Merck inks R&D tie with Mayo Clinic to pair clinical data and AI
Merck and the Mayo Clinic announced an R&D collaboration to combine Mayo Clinic Platform clinical and genomic datasets with Merck’s AI‑enabled virtual cell technologies to accelerate target...
Danaher to buy Masimo: $9.9B deal to bulk up diagnostics
Danaher Corp. agreed to acquire Masimo Corp. for $9.9 billion, offering $180 per share in cash — a 38% premium to Masimo’s prior close — to expand Danaher’s diagnostics and med‑tech footprint. The...
FDA accepts BMS protein degrader for review — regulatory milestone
The FDA accepted a Biologics License Application for Bristol Myers Squibb’s targeted protein degrader, formally initiating review, while separately issuing a rejection for a Disc Medicine rare...
Altesa raises $75M as Sanofi backs rhinovirus antiviral pivot
Altesa BioSciences closed a $75 million Series B round led by Forbion with participation from Sanofi to fund a Phase 2b study of vapendavir in COPD patients — a repositioning of a once‑failed...
FDA chief warns U.S. losing ground to China in early drug development
FDA Commissioner Marty Makary warned in a CNBC interview that the U.S. is falling behind China on early‑stage drug development, pointing to bottlenecks in hospital contracting, ethical reviews,...
FDA reverses course: Moderna flu vaccine accepted for review
The U.S. Food and Drug Administration told Moderna it will accept and review the company’s biologics license application for its mRNA influenza vaccine mRNA-1010, assigning a PDUFA target date of...
Psilocybin wins again: Compass edges toward regulatory filing
Compass Pathways reported a second positive Phase III readout for its synthetic psilocybin candidate COMP360 in treatment‑resistant depression, repeating efficacy seen in an earlier pivotal trial....
Altesa raises $75M — Sanofi joins Series B to back respiratory program
Altesa BioSciences closed a $75 million Series B to advance vapendavir, an oral antiviral it in‑licensed to prevent COPD exacerbations tied to rhinovirus infections; Forbion led the round and...
Korsana surfaces with $175M to pursue anti‑amyloid antibody
Korsana Biosciences emerged from stealth with $175 million in seed and Series A financing to develop KRSA‑028, a monoclonal antibody designed to clear amyloid‑beta plaques in Alzheimer’s disease...
Novartis bets big on macrocycles: UNP pact could top $1.8B
Novartis signed a research collaboration and licensing agreement with Unnatural Products (UNP) to apply UNP’s AI‑guided macrocyclic peptide platform toward cardiovascular disease targets. The deal...